SEVERE WX : Flood Warning View Alerts

Opioid addiction drugs severely underutilized, study finds

A study finds that despite the abili...

Posted: Jun 19, 2018 7:52 AM
Updated: Jun 19, 2018 7:52 AM

A study finds that despite the ability of medication-assisted treatment drugs like methadone and buprenorphine to save the lives of people who've overdosed on opioids, they continue to be underutilized.

The study, published Monday in the medical journal Annals of Internal Medicine, identified and tracked nearly 18,000 adults in Massachusetts who had gone to an emergency room because of a non-fatal drug overdose between 2012 and 2014. It found that only about 30% received any sort of Food and Drug Administration-approved medication-assisted treatment for opioid addiction.

Only three out of 10 people get some sort of FDA-approved drug for opioid addiction treatment

Drugs to treat opioid addiction can reduce risk of death by between 40% and 60%

Such treatment is considered the gold standard for opioid addiction and combines behavioral therapy with one of three approved drugs: methadone; buprenorphine, which is sold as Suboxone; and naltrexone, commonly sold as Vivitrol.

"We were shocked by the fact that so few people are getting medication," said Dr. Marc Larochelle, lead author of the study and an internist and researcher at Boston Medical Center's Grayken Center for Addiction.

Reducing risk of death

Larochelle and his colleagues found that when looking at the entire group a year after their overdoses, nearly 5% of the individuals had died, and about 2% of those deaths were due directly to opioids.

Overall, among those who received methadone, the one-year mortality rate dropped to 2.5%, and for those given buprenorphine, it dropped to 3% -- meaning, one year later, those who were treated with methadone or buprenorphine had reduced their risk of death by 60% and 40%, respectively.

There was no significant difference found in those patients who were treated with naltrexone. However, the study also cautioned that the number of patients using naltrexone was much more limited, which could have affected the finding.

Of the patients followed, researchers found that about 17% used buprenorphine, with median use of the drug around four months; 11% used methadone, with a median use of around five months; and just 6% used naltrexone, with a median use of about one month.

Caleb Banta-Green, who studies drug abuse epidemiology at the University of Washington's School of Public Health, said it's an important limitation, but he also noted that the limited use of just one month was still a noteworthy finding.

Dr. Sharon Stancliff agreed. "If you can't start a treatment, that says a lot about its effectiveness," said Stancliff, a practicing clinician in New York and a former adviser to the Harm Reduction Coalition. Neither she nor Banta-Green was involved in the new study.

There have been high dropout rates when it comes to naltrexone, possibly due to the fact that those starting the regimen cannot used any opioids for at least seven to 10 days. In contrast, methadone and buprenorphine can be started much sooner.

The hurdle in getting people to start naltrexone is also well-known. Randomized clinical trials have compared naltrexone to buprenorphine and found they were similarly effective in keeping people off opioids. But getting patients to start naltrexone has been difficult in these studies, as well.

Limited options when it comes to treatment

The latest study is the first side-by-side comparison in the United States of the impact these three drugs may have on mortality and accounts for how people actually use them.

"People chose to take these drugs out in the real world. And then this is what happened," Banta-Green said, calling it the real world apples-to-apples comparison that many clinicians have been hoping for.

Stancliff said, "this is a study that should be driving policy."

In recent years, Vivitrol, the long-acting injectable version of naltrexone, has become a popular treatment option in the criminal justice system -- and sometimes the only option.

"There's clearly no evidence it should be a preferred treatment, because it is clearly being pushed in some settings where people aren't being offered any other options," Larochelle said.

Fewer than half of all treatment programs prescribe one of the three FDA-approved medications, and only 3% provide all three. The FDA has taken additional steps to make these treatments more accessible. Most notably, in recent months, FDA Commissioner Dr. Scott Gottlieb has prioritized the development of new medication-assisted treatment option.

In the United States, the number of fatal opioid overdoses has continued to rise over the past two decades, and the most recent estimates have nearly 50,000 opioid-related overdoses in 2017. Opioid overdoses kill more people than breast cancer every year.

Larochelle and his colleagues also found that despite having had an overdose, 34% of people were prescribed opioids, and another 26% were prescribed benzodiazepines in the year after their overdoses.

What was clear from the study, Larochelle said, is that more people need to be accessing treatment. "We're not doing enough to reach enough people," he said.

Lafayette
Clear
32° wxIcon
Hi: 48° Lo: 29°
Feels Like: 25°
Kokomo
Clear
23° wxIcon
Hi: 44° Lo: 24°
Feels Like: 15°
Rensselaer
Clear
23° wxIcon
Hi: 41° Lo: 24°
Feels Like: 23°
Lafayette
Clear
32° wxIcon
Hi: 45° Lo: 25°
Feels Like: 25°
Danville
Clear
27° wxIcon
Hi: 46° Lo: 27°
Feels Like: 20°
Frankfort
Clear
27° wxIcon
Hi: 47° Lo: 26°
Feels Like: 19°
Frankfort
Partly Cloudy
27° wxIcon
Hi: 44° Lo: 25°
Feels Like: 19°
Monticello
Clear
26° wxIcon
Hi: 46° Lo: 27°
Feels Like: 19°
Monticello
Clear
26° wxIcon
Hi: 45° Lo: 28°
Feels Like: 19°
Logansport
Clear
25° wxIcon
Hi: 43° Lo: 25°
Feels Like: 25°
Dry, mild conditions continue
WLFI Radar
WLFI Temps
WLFI Planner

Indiana Coronavirus Cases

Data is updated nightly.

Cases: 663511

Reported Deaths: 12633
CountyCasesDeaths
Marion908511647
Lake48510882
Allen35951638
Hamilton32138398
St. Joseph30096513
Elkhart25423417
Vanderburgh21283379
Tippecanoe20096203
Johnson16380360
Porter16009272
Hendricks15855300
Clark11999181
Madison11764319
Vigo11636230
Monroe10363163
Delaware9854179
LaPorte9790197
Howard9075198
Kosciusko8574111
Bartholomew7479147
Warrick7430151
Hancock7418132
Floyd7226170
Wayne6645192
Grant6437157
Boone610389
Morgan6103125
Dubois5923111
Dearborn549068
Cass545899
Marshall5432105
Henry542593
Noble510178
Jackson465167
Shelby461490
Lawrence4189113
Gibson401781
Harrison401064
Clinton396553
Montgomery388483
DeKalb386478
Miami357663
Knox357585
Whitley349837
Huntington346277
Steuben339255
Wabash332376
Putnam331159
Ripley327762
Adams323949
Jasper317043
White297452
Jefferson295474
Daviess285596
Fayette271956
Decatur271088
Greene261680
Posey261431
Wells258575
Scott251250
Clay241544
LaGrange241270
Randolph225576
Spencer218030
Jennings215744
Washington212127
Sullivan203639
Fountain201842
Starke188451
Owen182853
Fulton179337
Jay178328
Carroll176519
Perry173435
Orange171150
Rush165322
Vermillion160842
Franklin159535
Tipton146841
Parke139416
Pike127833
Blackford120727
Pulaski106744
Newton96632
Brown95139
Benton92213
Crawford91013
Martin80214
Warren75814
Switzerland7558
Union67310
Ohio53911
Unassigned0433

COVID-19 Important links and resources

As the spread of COVID-19, or as it's more commonly known as the coronavirus continues, this page will serve as your one-stop for the resources you need to stay informed and to keep you and your family safe. CLICK HERE

Closings related to the prevention of the COVID-19 can be found on our Closings page.

Community Events